FASN and neoplasm: Through FASN-driven de novo lipogenesis, meCAFs supply pancreatic cancer cells with fatty acids that support membrane synthesis, energy production, and redox balance, thereby promoting tumor proliferation, survival, and resistance to therapy such as gemcitabine.